

Q² 4. (Amended) The preparation according to claim 1, characterized in that the excipient contains a transfer medium transporting the active ingredient.

6. (Amended) The preparation according to claim 1, characterized in that it is present in the form of a formula for topical application.

Q³ 7. (Amended) The preparation according to claim 1, characterized in that it is present in the form of an injection formula.

8. (Amended) The preparation according to claim 1, characterized in that it is intended for the pigmentation or depigmentation of skin or hair.

Q⁴ 10. (Amended) The use of the protein DCoH, the DNA and/or RNA for the coding of said protein, or DCoH antibodies or DCoH antiserum, as active ingredient for producing a preparation according to claim 1 for the treatment of pigmentation disorders of the human or animal body.

A marked-up version of the claims is shown as Exhibit A.